Patent: 6,096,871
Summary for Patent: 6,096,871
| Title: | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| Abstract: | Polypeptides that are cleared from the kidney and do not contain in their original form a Fc region of an IgG are altered so as to comprise a salvage receptor binding epitope of an Fc region of an IgG and thereby have increased circulatory half-life. |
| Inventor(s): | Leonard G. Presta, Bradley R. Snedecor |
| Assignee: | Genentech Inc |
| Application Number: | US08/422,093 |
| Patent Claims: | see list of patent claims |
Details for Patent 6,096,871
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | RAPTIVA | efalizumab | Injection | 125075 | October 27, 2003 | ⤷ Start Trial | 2017-08-01 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
